DermTech

DermTech is a commercial-stage diagnostics company with a mission to elevate dermatologic care through non-invasive genomic testing. Its core achievement is the commercialization of the DermTech Melanoma Test, a laboratory-developed test (LDT) with a 99% negative predictive value, trusted by over 3,000 clinicians and used on over 300,000 patients. The company's 'DermTech 2.0' strategy focuses on operational execution, scaling commercial adoption, and securing payer coverage, primarily within the Medicare and Veterans Health Administration systems. DermTech generates revenue from test sales performed in its centralized, CLIA-certified lab.

Integrated platform featuring a non-invasive Smart Sticker® for painless skin cell collection and a proprietary genomic lab assay (2-GEP) analyzing LINC00518 and PRAME expression to rule out melanoma with 99% negative predictive value.

Primary competition is the standard of care (surgical biopsy), not other genomic tests. Secondary competitors include non-invasive imaging devices like confocal microscopy, which require capital investment and specialized training. DermTech's key differentiators are its painless, scalable sample collection and objective genomic output designed for pre-biopsy triage.